What is the diagnosis and treatment for a patient with suspected organophosphate (OP) poisoning?

Diagnosis and Treatment of Organophosphate Poisoning

Diagnosis

Organophosphate poisoning is diagnosed based on history of exposure, characteristic clinical manifestations, and improvement with atropine administration. 1, 2

Clinical Presentation

The diagnosis relies on recognizing the classic cholinergic syndrome:

Muscarinic effects (most common):

• Miosis (pinpoint pupils) 3
• Excessive salivation and bronchorrhea 1, 3
• Bronchospasm and respiratory distress 1
• Bradycardia 1
• Altered mental status 3
• Fasciculations 3

Nicotinic effects:

• Muscle weakness and fasciculations 1
• Tachycardia (paradoxically, from nicotinic receptor overstimulation) 1
• Hypertension initially 1

Central nervous system effects:

• Seizures 1
• Agitation and confusion 1
• Altered consciousness 3

Diagnostic Pitfalls

• Do not wait for cholinesterase levels to initiate treatment—diagnosis is clinical and treatment must begin immediately 1, 2
• Recognize that tachycardia may be present despite organophosphate poisoning due to nicotinic effects, not just bradycardia 1
• Be aware that symptoms may recur or worsen due to continued absorption from the GI tract for up to 48-72 hours 1, 4

---

Immediate Management

Atropine must be administered immediately for severe manifestations—this is the life-saving intervention with Class 1, Level A evidence. 1, 5

Step 1: Personal Protection and Decontamination

• Healthcare workers must wear personal protective equipment (PPE) before patient contact—documented cases exist of providers requiring atropine, pralidoxime, and intubation after secondary exposure 1
• Remove all contaminated clothing immediately 1, 6
• Perform copious irrigation with soap and water for dermal exposure 1, 6
• For ingestion, perform gastric lavage with appropriate PPE—gastric contents can cause severe secondary poisoning in healthcare workers 1, 3
• Administer activated charcoal via nasogastric tube 3, 7

Step 2: Atropine Administration (First-Line, Immediate)

Initial dosing:

• Adults: 1-2 mg IV immediately (NOT the 0.5-1.0 mg used for typical bradycardia) 1, 5
• Children: 0.02 mg/kg IV (minimum 0.1 mg, maximum single dose 0.5 mg) 1, 5
• Higher doses are required in children than standard pediatric resuscitation doses 1, 5

Dose escalation protocol:

• Double the dose every 5 minutes until full atropinization is achieved 1, 5
• This is NOT fixed-dose repetition—aggressive doubling is critical 5
• Continue escalation regardless of heart rate—tachycardia is NOT a contraindication to continued atropine 1, 5

Endpoints of atropinization (all must be achieved):

• Clear chest on auscultation (no bronchorrhea) 5
• Heart rate >80 beats/min 5
• Systolic blood pressure >80 mm Hg 5
• Dry skin and mucous membranes 5
• Mydriasis (pupil dilation) 5

Maintenance therapy:

• Administer 10-20% of total loading dose per hour (up to 2 mg/hour in adults) 5
• Continuous infusion is preferred over intermittent boluses 5
• Cumulative doses may reach 10-20 mg in first 2-3 hours; some patients require up to 50 mg in 24 hours 5
• Maintain atropinization for at least 48 hours 5, 4

Step 3: Pralidoxime (2-PAM) Administration

Pralidoxime has Class 2a recommendation with Level A evidence and should be administered early. 1

Dosing:

• Adults: 1-2 g IV administered slowly, preferably by infusion 1
• Maintenance: 400-600 mg/hour for adults or 10-20 mg/kg/hour for children 1
• FDA labeling recommends 2 g IV loading dose followed by continuous infusion 4

Critical timing:

• Most effective when given early, before "aging" of the phosphorylated enzyme occurs 1
• Little benefit if given more than 36 hours after exposure termination 4
• Do not withhold pralidoxime when the class of poison is unknown—organophosphate vs. carbamate cannot be reliably distinguished clinically 1, 6

Mechanism:

• Reactivates acetylcholinesterase by competing with organophosphate-enzyme bond 1
• Reverses nicotinic effects (muscle weakness, some tachycardia) that atropine cannot address 1
• Always administer concurrently with atropine—pralidoxime alone is insufficient for respiratory depression 1

Step 4: Airway Management

Early endotracheal intubation is recommended for life-threatening poisoning. 1

Indications for intubation:

• Respiratory failure 3
• Depressed level of consciousness with inability to protect airway 3
• Hemodynamic instability 3
• Severe bronchorrhea or bronchospasm despite atropine 1

Critical pitfall:

• Avoid succinylcholine and mivacurium—these neuromuscular blockers are metabolized by cholinesterase and are contraindicated 1, 6, 4
• Use alternative agents for rapid sequence intubation 1

Step 5: Seizure Management

• Administer benzodiazepines (diazepam or midazolam) for seizures and agitation 1, 6
• Benzodiazepines are also useful to facilitate mechanical ventilation 1

---

Supportive Care

• Establish IV access and administer fluids for volume resuscitation 6
• Provide supplemental oxygen and ventilatory support as needed 6, 3
• Continuous cardiac monitoring for dysrhythmias 1, 6
• Monitor for aspiration pneumonia—occurs in 21% of cases 3

---

Monitoring and Complications

All patients must be observed for at least 48-72 hours due to risk of delayed complications. 1, 4

Intermediate Syndrome (19% of cases)

• Develops 24-96 hours after acute exposure 1, 3, 8
• Presents with delayed muscle weakness, respiratory failure 1
• Early recognition of respiratory distress is life-saving—watch for increasing respiratory rate (e.g., 22 to 38 breaths/min) 3
• Three deaths in one series occurred due to delayed intubation for intermediate syndrome 3

Rhabdomyolysis and Renal Complications

• Monitor creatine kinase and potassium levels 1
• Reddish urine indicates myoglobin (from muscle breakdown), not hemoglobin 1
• Treatment includes adequate hydration, forced diuresis, and urine alkalinization 1

Atropine-Related Complications

• Fever and hallucinations are expected adverse effects with high-dose atropine 1, 5
• Never withhold or discontinue atropine due to fever—inadequate atropinization leads to respiratory failure and death 1
• Risk of undertreating organophosphate poisoning far exceeds risk of atropine toxicity 1

Other Complications

• Aspiration pneumonia (21% of cases) 3
• Urinary tract infections 3
• Septic shock 3
• Acute pancreatitis (rare) 8
• Delayed polyneuropathy (may take up to 6 weeks for enzyme recovery) 5

---

Special Considerations

Carbamate vs. Organophosphate Poisoning

• Carbamates spontaneously dissociate from acetylcholinesterase; organophosphates cause permanent inactivation 1
• Clinical distinction is unreliable—treat all cases with both atropine and pralidoxime 1, 6
• Pralidoxime's role in carbamate poisoning is less clear, but should not be withheld when poison class is unknown 1, 6

Contraindicated Medications

• Avoid morphine, theophylline, aminophylline, reserpine, and phenothiazine-type tranquilizers 4
• Avoid succinylcholine and mivacurium for neuromuscular blockade 1, 6, 4

Hemodialysis

• No established role for hemodialysis in organophosphate poisoning 1
• Organophosphates are highly lipophilic, rapidly distribute to tissues, and bind irreversibly to acetylcholinesterase—poor candidates for extracorporeal removal 1
• Never delay antidote administration while considering hemodialysis 1

---

Treatment Algorithm Summary

1. Ensure PPE and decontaminate immediately 1
2. Atropine 1-2 mg IV (adults) or 0.02 mg/kg IV (children), double every 5 minutes until atropinization 1, 5
3. Pralidoxime 1-2 g IV loading dose, then 400-600 mg/hour infusion 1
4. Early intubation if respiratory failure, altered consciousness, or hemodynamic instability (avoid succinylcholine) 1, 3
5. Benzodiazepines for seizures and agitation 1
6. Gastric lavage and activated charcoal for ingestions 3, 7
7. Monitor continuously for 48-72 hours minimum 1, 4
8. Watch for intermediate syndrome (24-96 hours) and intubate early if respiratory rate increases 3